Stock Research for IPCI

IPCI

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

IPCI Stock Chart & Research Data

The IPCI chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the IPCI chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


IPCI Due diligence Resources & Stock Charts

The IPCI stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View IPCI Detailed Price Forecast - CNN Money CNN View IPCI Detailed Summary - Google Finance
Yahoo View IPCI Detailed Summary - Yahoo! Finance Zacks View IPCI Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View IPCI Trends & Analysis - Trade-Ideas Barrons View IPCI Major Holders - Barrons
NASDAQ View IPCI Call Transcripts - NASDAQ Seeking View IPCI Breaking News & Analysis - Seeking Alpha
Spotlight View IPCI Annual Report - CompanySpotlight.com OTC Report View IPCI OTC Short Report - OTCShortReport.com
TradeKing View IPCI Fundamentals - TradeKing Charts View IPCI SEC Filings - Bar Chart
WSJ View Historical Prices for IPCI - The WSJ Morningstar View Performance/Total Return for IPCI - Morningstar
MarketWatch View the Analyst Estimates for IPCI - MarketWatch CNBC View the Earnings History for IPCI - CNBC
StockMarketWatch View the IPCI Earnings - StockMarketWatch MacroAxis View IPCI Buy or Sell Recommendations - MacroAxis
Bullish View the IPCI Bullish Patterns - American Bulls Short Pains View IPCI Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View IPCI Stock Mentions - StockTwits PennyStocks View IPCI Stock Mentions - PennyStockTweets
Twitter View IPCI Stock Mentions - Twitter Invest Hub View IPCI Investment Forum News - Investor Hub
Yahoo View IPCI Stock Mentions - Yahoo! Message Board Seeking Alpha View IPCI Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for IPCI - SECform4.com Insider Cow View Insider Transactions for IPCI - Insider Cow
CNBC View IPCI Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for IPCI - OTC Markets
Yahoo View Insider Transactions for IPCI - Yahoo! Finance NASDAQ View Institutional Holdings for IPCI - NASDAQ


Stock Charts

FinViz View IPCI Stock Insight & Charts - FinViz.com StockCharts View IPCI Investment Charts - StockCharts.com
BarChart View IPCI Stock Overview & Charts - BarChart Trading View View IPCI User Generated Charts - Trading View




Latest Financial News for IPCI


Intellipharmaceutics Announces One-for-10 Reverse Stock Split
Posted on Thursday September 13, 2018

TORONTO, ONTARIO / ACCESSWIRE / September 13, 2018 / Intellipharmaceutics International Inc. (NASDAQ and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid-dosage drugs, announced today that it implemented a one-for-ten share consolidation (the "reverse split"). At a special meeting of the Company's shareholders held on August 15, 2018, the Company's shareholders granted the Company's Board of Directors discretionary authority to implement a consolidation of the issued and outstanding common shares of the Company on the basis of a consolidation ratio within a range from five (5) pre-consolidation common shares for one (1) post-consolidation common share to fifteen (15) pre-consolidation common shares for one (1) post-consolidation common share.


Intellipharmaceutics Closes US$0.5 Million Convertible Debenture Financing
Posted on Tuesday September 11, 2018

TSX: IPCI) (''Intellipharmaceutics'' or the ''Company''), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it issued in a private placement financing (the ''Financing'') an unsecured convertible debenture in the principal amount of US$0.5 million (the ''Debenture''), which will mature September 1, 2020. The Debenture bears interest at a rate of 10% per annum, payable monthly, is pre-payable at any time at the option of the Company, and is convertible at any time into common shares at a conversion price of US$0.30 per common share at the option of the holder. If the Debenture is fully converted into common shares of the Company, the shares would represent approximately 3.8% of the Company's currently issued common shares on a non-diluted basis.


Blog Exposure - Cambrex Announces Halo Pharma Acquisition
Posted on Wednesday July 25, 2018

LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want access to our free research report on Cambrex Corp. (NYSE: CBM), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CBM as the Company's latest news hit the wire. On July 23, 2018, the Company announced that it has inked a deal to acquire Halo Pharma, which is a leading dosage form Contract Development and Manufacturing Organization (CDMO), majority owned by funds managed by the private investment firm SK Capital Partners, for approximately $425 million in cash. Active-Investors.com is currently working on the research report for IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), which also belongs to the Healthcare sector as the Company Cambrex.


Intellipharmaceutics: Fiscal 2Q Earnings Snapshot
Posted on Tuesday July 17, 2018

On a per-share basis, the Toronto-based company said it had a loss of 7 cents. The extended-release drug developer posted revenue of $577,000 in the period. The company's shares closed at 47 cents. A year ...


Stock Market & Investing Books

Enter a stock symbol to view the stock details.